Bay Bridge, San Francisco, CA

Leadership

Setting The Direction

Management Team

Adam mendelsohn

Adam Mendelsohn, Ph.D.

CEO, Co-Founder, Chairman

Since founding Nano Precision Medical, Dr. Mendelsohn has served as its Chief Executive Officer and sets the strategic vision for the company.

Dr. Mendelsohn received his Ph.D. in bioengineering at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2011, during which he was awarded an NSF fellowship to perform research at Kyoto University, and published multiple peer-reviewed articles describing new treatment options for Type 1 diabetes through the immuno-isolated transplantation of insulin-producing cells under the direction of Professor Tejal A. Desai. While in graduate school, Dr. Mendelsohn served as the director for the Venture Innovation Program in Life Sciences, and completed his certificate in Management of Technology with the Haas School of Business.

Dr. Mendelsohn currently is a Technical Advisor to the Alfred E. Mann Institute for Biomedical Engineering at USC, a fellow of the Startup Leadership Program, the President of UCSF’s Graduate Division Alumni Association, and a board member of the Maestro Foundation.

Kayte fischer

Kayte Fischer, Ph.D.

CTO, Co-Founder

Since founding Nano Precision Medical, Dr. Fischer has been the Chief Technology Officer, coordinating technical development and scientific research with a larger strategic vision for the company.

Dr. Fischer completed her Ph.D. in the Therapeutic Micro and Nanotechnology Laboratory at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2010. Her award-winning research focused on novel adhesive properties of nanostructured materials in the context of gastrointestinal drug delivery. During her time in graduate school, Dr. Fischer completed the Management of Technology program through the Haas School of Business and the College of Engineering. She also has a designated emphasis in Nanoscale Science and Engineering and served as the president of the Berkeley Nanotechnology Club. Prior to attending graduate school, Dr. Fischer graduated with honors from the California Institute of Technology with a B.S. in Mechanical Engineering. Dr. Fischer also sits on the Associate Board of the Alameda Health System Foundation.

Lily peng

Lily Peng, M.D., Ph.D.

Consulting Vice President of Clinical Development, Co-Founder

Dr. Peng, a founder of Nano Precision Medical, considers and evaluates clinical opportunities for NanoPortal Technology.

Dr. Peng completed her M.D. at UC San Francisco in 2012 and her Ph.D. at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering in 2010. Her research focused on titania nanostructured surfaces and membranes as drug delivery and tissue engineering applications in the Therapeutic Micro and Nanotechnology Laboratory at UCSF, headed by Professor Tejal A. Desai. Dr. Peng’s previous research included studying cytoskeletal networks in neurodegeneration at Stanford and high-throughput 2D liquid mass spectrometry systems at Merck. Dr. Peng enjoys working on projects at the interface of engineering, medicine, and business, and spent several months evaluating new business plans for Burrill and Co. in 2010.

She graduated with Honors from Stanford in 2005 with a B.S. in Chemical Engineering and a minor in History. During her time at Stanford, Dr. Peng was awarded the Terman Scholar Award for Excellence in Engineering, the Merck Engineering and Technology Fellowship, and grants to complete two mural projects on the Stanford campus.

Wouter roorda

Wouter Roorda, Ph.D.

Vice President of Pharmaceutical Research and Development

Dr. Roorda leads development of drug formulations for use with NanoPortal Technology.

Dr. Roorda has more than 30 years of academic and industry experience with controlled drug delivery, medical devices, drug-device combinations and drug- and protein-formulation. In his Ph.D. studies, he developed and characterized a hydrogel-based drug delivery technology from polymer synthesis to testing in human volunteers. At Alza Corporation, he developed a number of formulations for implantable drug delivery systems intended for low molecular weight drugs as well as macromolecules.

As a research scientist at Guidant Corporation, Dr. Roorda pioneered some of the earliest studies on the Xience V drug eluting stent program, and after the acquisition by Abbott Labs, he assumed responsibility for new product concept generation and additional IP portfolio development as a director of R&D for the endovascular division. In this position he was a recipient of the Volwiler Outstanding Research Team award, the highest scientific team award at Abbott Laboratories.

Dr. Roorda has a Ph.D. from the University of Leiden, The Netherlands, and he is a registered Patent Agent.

Tomoyuki yoshie

Tomoyuki Yoshie, Ph.D.

Vice President of Device Research

Dr. Yoshie currently leads research related to the NanoPortal Technology at Nano Precision Medical.

Dr. Yoshie was most recently an Assistant Professor of Electrical and Computer Engineering at Duke University and directed the Duke Nanophotonics Laboratory. He received his Ph.D. degree in Electrical Engineering (minor in Physics) from the California Institute of Technology in 2004. Dr. Yoshie is a senior member of IEEE, and has more than 30 peer-reviewed journal publications, more than 20 patents, more than 20 invited and seminar talks, and more than 50 academic conference presentations.

Antwan gipson

Antwan Gipson

VP of Manufacturing and Quality

Mr. Gipson leads the fabrication and quality systems efforts related to the NanoPortal Technology at Nano Precision Medical.

Mr. Gipson brings over 20 years of industry experience in medical devices, pharmaceuticals, and combination products, including leadership roles in operations, manufacturing, engineering, logistics, and quality. He has developed several successful teams and participated in the development and market introduction of numerous products. Antwan has served in similar roles with both publicly traded companies and venture-backed start-ups such as Tautona Group, Cohesion Technologies (acquired by Angiotech Pharm.), and Fuisz Technologies (acquired by Biovail Corp.).

Antwan earned his B.Sc. in Engineering from Northern Michigan University, prior to serving in the United States Navy honorably, and has an MBA (emphasis applied research) from Angelo State University-Texas; including professional certificates in Quality Engineering, Production Inventory Management, and Lean Manufacturing.

Board Of Directors

Adam mendelsohn

Adam Mendelsohn, Ph.D.

CEO, Co-Founder, Chairman

Since founding Nano Precision Medical, Dr. Mendelsohn has served as its Chief Executive Officer and sets the strategic vision for the company.

Dr. Mendelsohn received his Ph.D. in bioengineering at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2011, during which he was awarded an NSF fellowship to perform research at Kyoto University, and published multiple peer-reviewed articles describing new treatment options for Type 1 diabetes through the immuno-isolated transplantation of insulin-producing cells under the direction of Professor Tejal A. Desai. While in graduate school, Dr. Mendelsohn served as the director for the Venture Innovation Program in Life Sciences, and completed his certificate in Management of Technology with the Haas School of Business.

Dr. Mendelsohn currently is a Technical Advisor to the Alfred E. Mann Institute for Biomedical Engineering at USC, a fellow of the Startup Leadership Program, the President of UCSF’s Graduate Division Alumni Association, and a board member of the Maestro Foundation.

Aaron mendelsohn

Aaron Mendelsohn, J.D.

Director

Mr. Mendelsohn arranges financing as a profession. Within the medical device field, he has been involved in several Al Mann companies assisting in capitalizing MiniMed, MRG, and Advanced Bionics. He is a founder and, since its inception, has been a director for Second Sight Medical Products, a publicly traded company commercializing the world's first prosthetic retina that restores vision to the profoundly blind. He served as a director of MRG from its formation in 1998 until it was sold in 2001 to Medtronic, Inc. for $430M. He served on the board of Advanced Bionics for many years until it was sold to Boston Scientific in 2004. He has served as a director of the Alfred Mann Institute for Biomedical Engineering at USC since its inception in 1998. At that institute, he is a member of the 3-man committee that serves as the CEO. He has served as Chairman of Data Display Products, Inc., a world leader in engineered LED lighting solutions, for over 10 years. He is a founder and has served, since 2007, as a director of Nanoprecision Holding Company, Inc., the world’s leader in manipulating materials at nanometer scale. He is a founder of Mastacopia, S.A., a start-up company founded in 2004, which is developing a new and better method of breast cancer screening.

Mr. Mendelsohn also is a founder and has served as Chairman of the Maestro Foundation since it was organized in 1983. The Maestro foundation is a leading non-profit musical philanthropic organization which hosts what is considered to be the nation’s premier chamber music series and lends approximately 100 professional-level instruments and bows to young, career-bound classical musicians. Mr. Mendelsohn holds a Bachelor’s Degree with honors from UCLA and holds a JD from Loyola University School of Law.

Dean baker

Dean Baker, Ph.D.

Director

Dr. Baker served on the board of directors of Advanced Bionics prior to its sale to Boston Scientific, was the founding director of the Alfred E. Mann Institute for Biomedical Engineering at USC, and currently serves on the board of directors for Semtech, a publicly traded semiconductor company.

Dr. Baker was also a vice president of Northrop Grumman for 16 years, overseeing a division with $1 billion in annual sales. Dr. Baker has continued to advise Nano Precision Medical in intellectual property, compensation, capitalization, and operation issues.